Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells

Ahrum Min(Seoul National University), Yung‐Jue Bang(Seoul National University Hospital)
Breast Cancer Research
March 6, 2015
10.1186/s13058-015-0534-y
Cited by 176

Related Papers

Therapeutic implication of HER2 in advanced biliary tract cancer
|Oncotarget|2016|86
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
|Cancer Research and Treatment|2018|31
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
|Cancer Research and Treatment|2020|21
TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
|Cancers|2020|8